Neurocrine Biosciences Inc (NBIX)

Industry Drug Manufacturers - Specialty & Generic
This stock can be held in an Investment ISA and an Investment Account
Sell

$123.61

Buy

$123.83

arrow-up$0.60 (+0.49%)

Prices updated at 29 May 2025, 20:31 EDT
| Prices minimum 15 mins delay
|
Prices in USD
Neurocrine Biosciences Inc engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States.
NASDAQ
arrow-up0.24%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Chairman
Dr. William H. Rastetter,PhD
CEO
Dr. Kyle W. Gano, PhD
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
1,800
Head office
6027 Edgewood Bend Court
San Diego
United States
92130
mobile
+1 858 617-7600
letter
ir@neurocrine.com
computer
Company website

Key personnel

Owner name
chevron-l-regular
chevron-r-regular
Salary
Dr. Eiry W. Roberts, M.D.
Chief Medical Officer
0.69m
Mr. Gary A. Lyons
Independent Director
0.07m
Dr. Kevin C. Gorman,PhD
Director
0.78m
Mr. Richard F. Pops
Independent Director
0.09m
Ms. Shalini Sharp
Independent Director
0.10m
Dr. William H. Rastetter,PhD
Chairman of the Board
0.10m
Ms. Christine A. Poon
Independent Director
0.08m
Mr. George J. Morrow
Independent Director
0.08m
Dr. Stephen A. Sherwin, M.D.
Independent Director
0.09m
Mr. Eric S. Benevich
Chief Commercial Officer
0.64m
Mr. Darin M. Lippoldt
Chief Legal Officer and Corporate Secretary
-
Ms. Leslie V. Norwalk, Esq.
Independent Director
0.08m
Dr. Kyle W. Gano, PhD
Director, President and Chief Executive Officer
0.70m
Mr. Matthew C. Abernethy
Chief Financial Officer and Principal Accounting Officer
0.68m
Ms. Julie S. Cooke
Chief Human Resources Officer
-
Ms. Johanna Mercier
Independent Director
0.07m
Mr. David W. Boyer
Chief Corporate Affairs Officer
-
Dr. Jude Onyia, PhD
Chief Scientific Officer
0.68m
Dr. Ingrid Delaet, PhD
Chief Regulatory Officer
-

Top 5 shareholders

Owner name
chevron-l-regular
chevron-r-regular
No. of shares
BlackRock Inc14,682,394
Vanguard Group Inc9,941,887
BlackRock Fund Advisors7,068,243
Dodge & Cox5,534,624
State Street Corp4,862,116

Director dealings

Date
chevron-l-regular
chevron-r-regular
Action
31 Dec 2024-
31 Dec 2024-
31 Dec 2024-
17 Dec 2024-
17 Dec 2024-
17 Dec 2024-
17 Dec 2024-
17 Dec 2024-
29 Nov 2024-
29 Nov 2024-
29 Nov 2024-
08 Nov 2024-
08 Nov 2024-
08 Nov 2024-
08 Nov 2024-
08 Nov 2024-
08 Nov 2024-
08 Nov 2024-
08 Nov 2024-
04 Nov 2024-
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.